Biosimilars

Extrapolating the Evidence. A Roundtable Discussion.

Patents for several biologics will soon expire, paving the way for biosimilars—defined as highly similar versions of already licensed or approved biological therapies. The aim of developing a biosimilar is to establish similarity in terms of quality, safety, and efficacy rather than to reestablish clinical benefit. This introduces a different way of thinking about drug development for clinicians, who will ultimately analyze and integrate biosimilars into existing treatment paradigms. As such, oncologists across specialties need to understand the core concepts of biosimilarity, including extrapolation—the approval of a biosimilar for use in an indication held by the previously approved biological therapy (deemed the reference product), but not directly studied in a comparative clinical trial with the biosimilar. Extrapolation is the highly scrutinized scientific rationale that bridges data collected across indications and has important implications in oncology, where biological anticancer therapies are currently licensed for use across tumor types and in supportive care.

In this roundtable discussion, experts specializing in breast, lung, hematologic, and gynecologic cancers highlight the scientific rationale behind biosimilarity and extrapolation. They provide practical insight into the implications of biosimilars for clinical practices, including their potential to expand access to important medicines for patients and clinicians.


Extrapolating the Evidence. A Roundtable Discussion

12-22 FINAL full


Part 1: Introduction

Duration: 2:03

Part 5: Conclusion

Duration: 0:45

Participants in this video received financial support from Pfizer Inc. The opinions or views expressed in this video are solely those of the participants and do not necessarily reflect the opinions or recommendations of Pfizer Inc.

Editorial support to prepare this video was provided by Phase Five Communications and funded by Pfizer Inc.

Search this site